| 国产重组(酵母)乙型肝炎疫苗免疫效果观察 |
| |
| 引用本文： | 吴维寿,应庆茹,顾丽娟,徐元,尤莉,刘崇柏,曹惠霖,林曦敏,徐志一.国产重组(酵母)乙型肝炎疫苗免疫效果观察[J].中国计划免疫,2001,7(5):259-261. |
| |
| 作者姓名： | 吴维寿 应庆茹 顾丽娟 徐元 尤莉 刘崇柏 曹惠霖 林曦敏 徐志一 |
| |
| 作者单位： | 吴维寿（上海市黄浦区疾病预防控制中心上海 200011）
应庆茹（上海市黄浦区疾病预防控制中心上海 200011）
顾丽娟（上海市黄浦区疾病预防控制中心上海 200011）
徐元（上海市黄浦区疾病预防控制中心上海 200011）
尤莉（上海市黄浦区疾病预防控制中心上海 200011）
刘崇柏（中国预防医学科学院病毒学研究所北京 100052）
曹惠霖（中国预防医学科学院病毒学研究所北京 100052）
林曦敏（复旦大学公共卫生学院上海 200032）
徐志一（复旦大学公共卫生学院上海 200032） |
| |
| 摘 要： | 为研究和比较国产重组(酵母)乙型肝炎(乙肝)疫苗与血源乙肝疫苗的免疫效果,采用单纯随机方法,于免疫后1年对重组(酵母)乙肝疫苗接种的新生儿进行随访观察,采血检测乙肝病毒表面抗原(HBsAg)、乙肝病毒表面抗体(抗-HBs)、乙肝病毒核心抗体(抗-HBc).HBsAg阳性母亲所生的儿童其HBsAg阳性率为5.2%(4/77),抗-HBs阳性率为83.3%(65/78),疫苗保护效果为91.3%;HBsAg阴性母亲所生的儿童其HBsAg阳性率为0.9%(1/114),抗-HBs阳性率为97.4%(111/114),疫苗保护效果为79.5%.重组(酵母)乙肝疫苗有较好的近期保护效果和免疫原性,与以前使用的血源乙肝疫苗相当.
|
| 关 键 词： | 重组(酵母)乙肝疫苗 乙型肝炎病毒表面抗原 保护效果 |
| 文章编号： | 1006-916(2001)05-0259-03 |
| 修稿时间： | 2001年5月28日 |
Efficacy Study of Domestic Yeast-d erived Recombinant Hepatitis B Vac cine |
| |
| WU Wei-shou,YING Qing-ru,GU Li-juan,et al Center for Disease Prevention and Control of Huangpu District,Shanghai ,China..Efficacy Study of Domestic Yeast-d erived Recombinant Hepatitis B Vac cine[J].Chinese Journal of Vaccines and Immunization,2001,7(5):259-261. |
| |
| Authors: | WU Wei-shou YING Qing-ru GU Li-juan et al Center for Disease Prevention and Control of Huangpu District Shanghai China |
| |
| Institution: | WU Wei-shou,YING Qing-ru,GU Li-juan,et al Center for Disease Prevention and Control of Huangpu District,Shanghai 200011,China. |
| |
| Abstract: | For investigating the immune efficacy of domestic yeast-derived recombinant hepatitis B vaccine that has replaced the plasma-derived one,we followed up for one year the children who had received the yeast-derived recombinant hepatitis B vaccine at their birth Blood sample was taken from each subject and tested for HBsAg,anti-HBs and anti-HBc HBsAg positive rate in children born to HBsAg positive mothers was 5 2%(4/77), anti-HBs positive rate was 83 3%(65/78)and the protective efficacy was 91 3% For children born to HBsAg-negative mothers,thses figures were 0 9%(1/114),97 4%(111/114)and 79 5%,respectively Thus,the yeast-derived recombinant hepatitis B vaccine is as good as plasma-derived one in terms of short-term efficacy and immunogenicity |
| |
| Keywords: | Yeast-derived recombinant hepatitis B vaccine HBsAg Protective efficacy |
| 本文献已被 CNKI 等数据库收录！ |
|
